The objective of this study was to determine the need for repeat prostatic biopsies in men whose initial biopsy results revealed no evidence of cancer or atypia. We evaluated 1,136 men who underwent 1 or more prostatic biopsies in a longitudinal prostate specific antigen (PSA) based prostate cancer screening study that called for biopsy if the serum PSA level was greater than 4.0 ng./ml. (Hybritech assay) and findings on rectal examination or ultrasonography were abnormal or suspicious for cancer. Of the 1,136 men who underwent prostatic biopsy 391 (34%) had prostate cancer on the initial biopsy. Of 427 men who had negative initial biopsy results, a persistent serum PSA level of greater than 4.0 ng./ml. and abnormal rectal or ultrasound examination findings 82 (19%) had cancer on biopsy 2. Of 203 men with persistent abnormalities 16 (8%) had cancer on biopsy 3 and 6 of 91 (7%) had cancer on biopsy 4 or later. Thus, 96% of the cancers were detected through either biopsy 1 or 2. The median initial PSA level, followup PSA levels and the yearly rate of change in PSA were significantly greater in men whose cancer was detected compared with those of men whose cancer was not detected (6.4 versus 5.4 ng./ml., 7.4 versus 6.6 ng./ml. and 1.1 versus 0.7 ng./ml. per year, respectively). There was a trend for a higher percentage of tumors detected through serial screening to be pathologically organ confined with those detected through initial screening (73% versus 62%, p = 0.07). We conclude that men with a persistently elevated serum PSA value after an initial negative prostatic biopsy should routinely undergo at least 1 repeat biopsy to exclude adequately the presence of detectable prostate cancer.
[1]
W. Catalona,et al.
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
,
1991,
The New England journal of medicine.
[2]
J. Goméz,et al.
Serum prostate specific antigen as pre-screening test for prostate cancer.
,
1992,
The Journal of urology.
[3]
G. Chodak,et al.
Assessment of screening for prostate cancer using the digital rectal examination.
,
1989,
The Journal of urology.
[4]
R. Vessella,et al.
Screening for prostatic carcinoma with prostate specific antigen.
,
1992,
The Journal of urology.
[5]
I. Thompson,et al.
Adenocarcinoma of the prostate: results of routine urological screening.
,
1984,
The Journal of urology.
[6]
W. Catalona,et al.
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
,
1993,
JAMA.
[7]
E. Metter,et al.
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
,
1992,
JAMA.
[8]
O. Wangensteen,et al.
Evaluation of annual examinations in the detection of cancer. Special reference to cancer of the gastrointestinal tract, prostate, breast, and female generative tract.
,
1960,
JAMA.
[9]
D. Hosmer,et al.
Applied Logistic Regression
,
1991
.